Category Archives: TPX-0005: TP Therapeutics

Clinical trial of TPX-0005 from TP Therapeutics

As of March 6, 2017, lists a Trial of TPX-0005 which targets ALK, ROS1, and NTRK 1-3. At this time there are four trial sites at: UC Irvine Cancer center, University of Colorado, Denver, Massachusetts General Hospital, and Memorial … Continue reading

Posted in Brain metastases, Lung cancer, Potential Treatments, Research, TPX-0005: TP Therapeutics | Leave a comment